Nathalie Lachenal

3 та иш

Médecins Sans Frontières, Geneva, Switzerland

1. How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial

   Ilaria Motta, Martina Cusinato, Andrew Ludman +15

   МақолаCardiac electrophysiology and arrhythmiasAntimicrobial Agents and Chemotherapy20240 иқтибос

   ABIABI:AkademIndex/openalex/2024.article.000869

2. The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings—A Prospective Cohort Study in Belarus and Uzbekistan

   Animesh A. Sinha, Robert J. Klebe, Michael L. Rekart +22

   МақолаTuberculosis Research and EpidemiologyClinical Infectious Diseases20250 иқтибос

   ABIABI:AkademIndex/openalex/2025.article.000230

3. Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

   Anthony J. Garcia‐Prats, Maria Garcia‐Cremades, Vivian Cox +97

   Шарҳ мақолаTuberculosis Research and EpidemiologyThe Lancet Child & Adolescent Health20250 иқтибос

   ABIABI:AkademIndex/openalex/2025.review-article.000036